Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-03-05 am EST			5-day change	1st Jan Change
248.65 ^DKK	+1.30%		+4.21%	-23.55%

Mar. 05	Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial	DJ
Mar. 05	Roche, Zealand's obesity drug shows up to 10.7% weight loss in mid-stage trial	RE

Berenberg Lowers Price Target for Novo Nordisk to 360 Danish Kroner (415), Reiterates Buy - BN

Published on 02/12/2026 at 03:48 am EST

Finwire - Translated by Marketscreener - See original

NOVO NORDISK A/S

+1.30%

Berenberg has lowered its price target for Novo Nordisk to 360 Danish kroner (previously 415), while reiterating its buy recommendation - BN

Latest news about Novo Nordisk A/S

Mar. 05	Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial	DJ
Mar. 05	Roche, Zealand's obesity drug shows up to 10.7% weight loss in mid-stage trial	RE
Mar. 05	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
Mar. 05	Lilly launches employer-connect platform to broaden weight-loss drug access	RE
Mar. 05	ISS Recommends Against Re-Election of Novo Nordisk Chairman - BN	FW
Mar. 04	GLP-1 drugs protect against new or worsening addictions, large study shows	RE
Mar. 04	European Stocks Rebound in Wednesday Trading Despite Escalation in Middle East War	MT
Mar. 04	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Potential Middle East Diplomacy Reports	MT
Mar. 04	When Talk of Talks Moves Markets
Mar. 04	Novo Nordisk Reportedly Warned Over Use of Misleading Claims in Ozempic Ad	MT
Mar. 04	Drugmaker Aspen targets Mounjaro approval in sub-Saharan Africa this year	RE
Mar. 04	FDA Criticizes Novo Nordisk Over Ozempic Advertisement - BN	FW
Mar. 04	Remember 2022
Mar. 03	US FDA warns Novo again about misleading drug advertising	RE
Mar. 03	Novo Nordisk executive received 'untitled letter' from FDA concerning an advertising campaign for Ozempic	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

69,150

Sector

Pharmaceuticals

Calendar

Mar. 27 - Ex-dividend date - 7.95 DKK

More about the company